“Our collaboration with Dicerna to discover and develop GalXC RNAi therapies, which have the potential to inhibit uncontrolled activation of the complement system in new ways, represents an exciting ...

“ With more than 20 years of experience, Alexion is a clear leader in the field of complement biology, and we are very pleased by our collaboration’s success to date in identifying potential new GalXC ...